Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PUSHKAR M KANADE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144506445
CMS profile
879631
Location
CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$15,559.15

44 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PUSHKAR M KANADE

NPI 1144506445 · CMS profile ID 879631

Allopathic & Osteopathic Physicians / Internal Medicine

CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144506445?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PUSHKAR M KANADE, NPI 1144506445, CMS profile ID 879631. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144506445?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PUSHKAR M KANADE, NPI 1144506445, CMS profile ID 879631. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144506445?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PUSHKAR M KANADE, NPI 1144506445, CMS profile ID 879631, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1144506445?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

44 matching records · $15,559.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 44 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–44 of 44.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $2,100.0012/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784105 CMS
Fresenius USA Marketing, Inc. $16.0912/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154211820 CMS
Amgen Inc. $16.3711/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784097 CMS
Ardelyx, Inc. $250.0009/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687779 CMS
Ardelyx, Inc. $35.0009/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687781 CMS
Ardelyx, Inc. $35.3909/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687783 CMS
Ardelyx, Inc. $35.3909/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687785 CMS
Ardelyx, Inc. $50.0009/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687787 CMS
Ardelyx, Inc. $2,400.0009/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687789 CMS
Ardelyx, Inc. $283.8609/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687769 CMS
Ardelyx, Inc. $351.3009/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687771 CMS
Ardelyx, Inc. $610.8709/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687773 CMS
Ardelyx, Inc. $124.9909/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687775 CMS
Ardelyx, Inc. $1,200.0009/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687777 CMS
SCPHARMACEUTICALS INC. $24.5209/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132296538 CMS
Fresenius USA Marketing, Inc. $15.4608/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154211818 CMS
Mallinckrodt Hospital Products Inc. $19.0708/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145089587 CMS
Alexion Pharmaceuticals, Inc. $18.7608/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094003351 CMS
Amgen Inc. $25.0008/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784035 CMS
Amgen Inc. $25.0008/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784043 CMS
Amgen Inc. $350.0008/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784051 CMS
Amgen Inc. $45.0008/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784062 CMS
Amgen Inc. $55.0008/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784070 CMS
Amgen Inc. $654.2008/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784081 CMS
Amgen Inc. $150.0008/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784019 CMS
Amgen Inc. $476.5208/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784027 CMS
Amgen Inc. $2,100.0007/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784089 CMS
Amgen Inc. $21.0707/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784009 CMS
Travere Therapeutics, Inc. $12.4906/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149909099 CMS
Ardelyx, Inc. $20.8306/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687767 CMS
Fresenius USA Marketing, Inc. $17.6505/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154211826 CMS
Amgen Inc. $9.1604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115783991 CMS
Amgen Inc. $1,750.0004/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115784001 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.6804/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086217987 CMS
Alexion Pharmaceuticals, Inc. $20.8503/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094050701 CMS
Amgen Inc. $9.5003/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115783973 CMS
Fresenius USA Marketing, Inc. $17.3402/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154211824 CMS
Ardelyx, Inc. $18.0702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146687765 CMS
Amgen Inc. $16.0601/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115783963 CMS
Amgen Inc. $2,100.0001/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115783982 CMS
Travere Therapeutics, Inc. $4.3801/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149909095 CMS
Travere Therapeutics, Inc. $31.0001/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149909102 CMS
Fresenius USA Marketing, Inc. $16.6201/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154211822 CMS
Travere Therapeutics, Inc. $2.6601/04/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149909091 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $278.46 6
PY2022 $209.73 11
PY2023 $10,131.26 35
PY2024 $15,559.15 44
PY2025 $5,315.91 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $362,982.61 42
PY2024 Principal investigator $25,154.84 14
PY2023 Principal investigator $41,380.36 45
PY2022 Principal investigator $127,066.20 120
PY2021 Principal investigator $6,314.90 3
PY2020 Principal investigator $80,106.36 12
PY2019 Principal investigator $78,304.52 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $484.30 12/05/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335890
Principal investigator 1 CSL Behring $94.69 10/28/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335590
Principal investigator 1 CSL Behring $31.08 09/05/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335670
Principal investigator 1 CSL Behring $2,197.70 08/05/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334978
Principal investigator 1 CSL Behring $17.14 07/29/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335498
Principal investigator 1 CSL Behring $1,955.43 07/08/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142335396
Principal investigator 1 Boehringer Ingelheim International GmbH $7,350.00 07/03/2024 Non-covered Recipient Entity
Great Plains Health
Phase III Renal Outcomes No dispute reported 06/30/2026 1101069507
Principal investigator 1 CSL Behring $4,050.00 06/19/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334852
Principal investigator 1 CSL Behring $1,562.00 04/26/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334788
Principal investigator 1 CSL Behring $1,919.00 04/26/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334790
Principal investigator 1 CSL Behring $3,000.00 04/26/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334792
Principal investigator 1 CSL Behring $900.00 04/26/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334794
Principal investigator 1 CSL Behring $500.00 04/26/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334796
Principal investigator 1 CSL Behring $1,093.50 04/26/2024 Non-covered Recipient Entity
Frenova, LLC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1142334798